MarketLens

What Do the Povorcitinib Trial Results Mean for Incyte

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Do Karyopharm's Mixed SENTRY Trial Results Mean for Myelofibrosis Treatment

5 months ago

What Do the Latest SUMMIT Trial Data Mean for Bezuclastinib

5 months ago

What Do UNFI's Mixed Q2 Results Really Mean for Investors

5 months ago

What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors

5 months ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer's oral drug restored skin pigmentation in two late-stage vitiligo trials, paving the way for regulatory submissions in the autoimmune skin disease.

PFE

Stock News•4 weeks ago

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Incyte reported Q2 2026 financial results, with total revenues rising 12% YoY to $1.2B, driven by Jakafi sales growth and Opzelura's continued expansion.

INCY

Stock News•1 months ago

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Celldex reported Phase II barzolvolimab results in prurigo nodularis alongside a trial discontinuation. The mixed update could cloud the drug's regulatory path.

CLDX

Stock News•1 months ago

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune's EVO756 CSU miss casts doubt on its pipeline, but a healthy balance sheet and positive Phase 2a AD data for EVO301 provide a potential catalyst.

EVO